Raloxifene for postmenopausal osteoporosis

Medical Letter on Drugs and Therapeutics

Volumn 40, Issue 1022, 1998, Pages 29-30

  Abramowicz, Mark ^f   Rizack, Martin A ^a   Goodstein, Donna ^f   Faucard, Amy ^f   Hansten, Philip D ^b   Steigbigel, Neal H ^c   Mukherjee, Sandip K ^d   Smoller, Jordan W ^e   Zuccotti, Gianna ^c   Aschenbrenner, Marianne ^f  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; COLESTYRAMINE; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE; WARFARIN;

BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE CRAMP; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; RECEPTOR UPREGULATION; SHORT SURVEY; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 0013650919     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (3)

1. M Brennan, Chem Eng News, 75:11, December 15, 1997; K Paech et al, Science, 277:1508, September 5, 1997
2. M Brennan, Chem Eng News, 75:11, December 15, 1997; K Paech et al, Science, 277:1508, September 5, 1997
3. PD Delmas et al, N Engl J Med, 337:1641, Dec 4, 1997